Comparison of dose-dense ABVD and standard ABVD in the treatment of early unfavorable and advanced Hodgkin's lymphoma: A retrospective analysis

Yun Xia Tao, San Yuan Sun, Su Yi Kang, Li Qiang Zhou, Yuan Kai Shi, Ye Xiong Li, Yan Sun

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

This retrospective analysis compared standard regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with the dose-dense ABVD regimen (ABVD-21) in terms of efficacy and toxicity. Patients who had early-stage unfavorable or advanced Hodgkin's lymphoma (HL) according to German Hodgkin Study Group criteria from March 1999 to February 2011 were analyzed for treatment response, long-term survival and hematological toxicity. There were 85 patients in the ABVD-21 group and 118 patients in the ABVD group respectively. The complete remission rates after completion of treatment were 92.9% and 90.7% for ABVD-21 and ABVD, respectively. During a median follow-up period of 62 months, no significant difference was found in projected 10-year progression-free survival (PFS) and overall survival (OS) rates (84.7% and 94.1% respectively for ABVD-21; 81.4% and 91.5% for ABVD). Subgroup analyses showed that ABVD-21 was significantly better than ABVD for patients with IPS'3 in terms of PFS and OS rates. Grade 3 to 4 leukopenia (51.8% vs. 28.8%, P=0.001) and neutropenia (57.6% vs. 39.0%, P=0.009) were more common with ABVD-21. We were led to conclude that dose-dense ABVD did not result in better tumor control and overall survival than did ABVD for early-stage unfavorable HL. However, patients at high risk, for example, with IPS'3, may benefit from dose-dense ABVD.

Original languageEnglish
Pages (from-to)260-264
Number of pages5
JournalJournal of Huazhong University of Science and Technology - Medical Science
Volume34
Issue number2
DOIs
StatePublished - Apr 2014

Keywords

  • Hodgkin's lymphoma
  • dose-dense ABVD
  • retrospective analysis
  • standard ABVD

Fingerprint

Dive into the research topics of 'Comparison of dose-dense ABVD and standard ABVD in the treatment of early unfavorable and advanced Hodgkin's lymphoma: A retrospective analysis'. Together they form a unique fingerprint.

Cite this